Therapeutics News and Research

RSS
Authors explain why health care reform initiative should include CER

Authors explain why health care reform initiative should include CER

7 Jan 2010
UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

7 Jan 2010
Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

7 Jan 2010
Pfizer and Strides Arcolab announce new collaboration

Pfizer and Strides Arcolab announce new collaboration

6 Jan 2010
BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

6 Jan 2010
Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

6 Jan 2010
AMT receives Innovation Credit to develop gene therapy treatment for DMD

AMT receives Innovation Credit to develop gene therapy treatment for DMD

6 Jan 2010
Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

6 Jan 2010
DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

5 Jan 2010
ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

5 Jan 2010
Bioject Medical Technologies collaborates with MPI Research to explore drug and device opportunities

Bioject Medical Technologies collaborates with MPI Research to explore drug and device opportunities

5 Jan 2010
Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

5 Jan 2010
Scientists determine how RNAi, a biological response to RNA, can regulate gene expression

Scientists determine how RNAi, a biological response to RNA, can regulate gene expression

5 Jan 2010
Positive results from Pearl Therapeutics' PT005 Phase 2a trial for COPD

Positive results from Pearl Therapeutics' PT005 Phase 2a trial for COPD

5 Jan 2010
Elusys Therapeutics signs contract to complete the final development of Anthim

Elusys Therapeutics signs contract to complete the final development of Anthim

5 Jan 2010
Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

4 Jan 2010
Revance Therapeutics closes $35 million Series D financing

Revance Therapeutics closes $35 million Series D financing

4 Jan 2010
Anesiva to file a petition for relief under the Bankruptcy Code

Anesiva to file a petition for relief under the Bankruptcy Code

4 Jan 2010
Bacterial enzyme decreases cocaine desire

Bacterial enzyme decreases cocaine desire

3 Jan 2010
Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

3 Jan 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback